GoAI
Get started
Mangoceuticals, Inc. logo

Mangoceuticals, Inc.

MGRX

NASDAQHealthcareMedical - Healthcare Information Services

Open in GoAI

Previous close

$0.422

+$0.0363 · +9.41%

Aug 21, 4:00 PM ET

Pre-market

$0.3638

−$0.0582 · -13.79%

Aug 24, 8:37 AM ET

MGRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

35

Expensive

Momentum

23

Weakening

Sentiment

51

Mixed

Risk resilience

17

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Jacob D. Cohen
Listed since
Mar 21, 2023
Employees
3

Market position

Day range

Current $0.422

52-week range

Current $0.422

Open
$0.3813
Previous close
$0.3857
Volume
1.15M
0.12× average
Average volume
9.68M
Average daily volume
Market cap
7.16M USD
Beta
2.1
Market reference 1
50-day average
$0.4336
-2.67% below average
200-day average
$0.5934
-28.88% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.27M USD
EV / EBITDA
-0.33×
Earnings yield
-276.98%
Free cash flow yield
-78.50%

Profitability & efficiency

Return on equity
-135.81%
Return on assets
-128.30%
Return on invested capital
-123.53%

Financial health

Current ratio
1.74×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2303%-6662%-15628%-24593%Gross margin, FY2022: 54.26%Gross margin, FY2023: 58.99%Gross margin, FY2024: 61.70%Gross margin, FY2025: 54.91%Operating margin, FY2022: -22279.70%Operating margin, FY2023: -1260.28%Operating margin, FY2024: -1294.42%Operating margin, FY2025: -4200.46%Net margin, FY2022: -22352.11%Net margin, FY2023: -1259.40%Net margin, FY2024: -1413.60%Net margin, FY2025: -4526.86%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 54.26%. Gross margin FY2023 58.99%. Gross margin FY2024 61.70%. Gross margin FY2025 54.91%. Operating margin FY2022 -22279.70%. Operating margin FY2023 -1260.28%. Operating margin FY2024 -1294.42%. Operating margin FY2025 -4200.46%. Net margin FY2022 -22352.11%. Net margin FY2023 -1259.40%. Net margin FY2024 -1413.60%. Net margin FY2025 -4526.86%.

Income trends

Revenue

456.02K USD-25.96%

Operating income

−19.15M USD-140.28%

Net income

−20.64M USD-137.12%
Income trends across reported periods2.87M USD−5.68M USD−14.23M USD−22.78M USDRevenue, FY2022: 8.94K USDRevenue, FY2023: 731.49K USDRevenue, FY2024: 615.87K USDRevenue, FY2025: 456.02K USDOperating income, FY2021: −17.52K USDOperating income, FY2022: −1.99M USDOperating income, FY2023: −9.22M USDOperating income, FY2024: −7.97M USDOperating income, FY2025: −19.15M USDNet income, FY2021: −17.7K USDNet income, FY2022: −2M USDNet income, FY2023: −9.21M USDNet income, FY2024: −8.71M USDNet income, FY2025: −20.64M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 8.94K USD. Revenue FY2023 731.49K USD. Revenue FY2024 615.87K USD. Revenue FY2025 456.02K USD. Operating income FY2021 −17.52K USD. Operating income FY2022 −1.99M USD. Operating income FY2023 −9.22M USD. Operating income FY2024 −7.97M USD. Operating income FY2025 −19.15M USD. Net income FY2021 −17.7K USD. Net income FY2022 −2M USD. Net income FY2023 −9.21M USD. Net income FY2024 −8.71M USD. Net income FY2025 −20.64M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue456.02K USD615.87K USD731.49K USD8.94K USD—
Cost of goods sold205.64K USD235.91K USD299.99K USD4.09K USD—
Gross profit250.39K USD379.96K USD431.5K USD4.85K USD—
Selling, general, and administrative16.72M USD7.9M USD5.42M USD2M USD17.52K USD
Operating expenses19.41M USD8.35M USD9.65M USD2M USD17.52K USD
Interest income——6.47K USD——
Interest expense103.51K USD13.7K USD—6.47K USD181 USD
Depreciation and amortization1.72M USD721.53K USD24.89K USD3.86K USD—
Operating income−19.15M USD−7.97M USD−9.22M USD−1.99M USD−17.52K USD
Net income−20.64M USD−8.71M USD−9.21M USD−2M USD−17.7K USD

Company facts updated Aug 24, 2026.

MGRX news

businesswire.com

MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Mangoceuticals, Inc. (NASDAQ: MGRX) and Nuclea Energy Inc. Halper Sadeh encourages Mangoceuticals shareholders to…

Read source
globenewswire.com

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to…

Read source
newsfilecorp.com

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to…

Read source
newsfilecorp.com

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

The MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter…

Read source
globenewswire.com

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter…

Read source
globenewswire.com

Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor…

Read source

MGRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MGRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
68.55K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research MGRX

research.disclaimer